Company Description
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation.
In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
| Country | United States |
| Founded | 1982 |
| IPO Date | Apr 30, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 79 |
| CEO | Michael F. Brigham |
Contact Details
Address: 56 Evergreen Dr Portland, Maine 04103 United States | |
| Phone | (207) 878-2770 |
| Website | immucell.com |
Stock Details
| Ticker Symbol | ICCC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000811641 |
| CUSIP Number | 452525306 |
| ISIN Number | US4525253062 |
| Employer ID | 01-0382980 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Michael F. Brigham | President, Chief Executive Officer, Principal Financial Officer, Treasurer, Secretary and Director |
| Bobbi Jo Brockmann | Vice President of Sales and Marketing and Director |
| Elizabeth S. Toothaker | Director of Finance and Administration and Controller |
| A. Gustavo Scaffa | Senior Director of Quality |
| John W. Zinckgraf | Director of Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 9, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| May 22, 2024 | SCHEDULE 13D | Filing |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | 424B2 | Prospectus |
| Apr 10, 2024 | 424B2 | Prospectus |